Matthew Rubinstein1,*, Madeline Lauren Hong1, Rishi Kumar Nanda1, Daniel Thomas Jones1, Hazem Aboaid2, Yin Mon Myat3, Kyaw Zin Thein4
Oncology Research, Vol.33, No.11, pp. 3161-3183, 2025, DOI:10.32604/or.2025.067791
- 22 October 2025
Abstract The ever-expanding development of tissue-agnostic therapies which target malignancies based on specific mutations rather than tissue origin have transformed the landscape of oncology. The purpose of this review is to explore the impact, safety, and challenges of tissue-agnostic therapies including pembrolizumab, dostarlimab, larotrectinib, entrectinib, repotrectinib, dabrafenib plus trametinib, selpercatinib, and trastuzumab deruxtecan. As the therapeutic arsenal continues to grow, it is crucial to understand how these therapies truly benefit patients and to address the barriers that stand in the way of making them more widely available. Although these therapies have shown effectiveness across multiple cancer More >